Csilla Olah
Overview
Explore the profile of Csilla Olah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olah C, Shmorhun O, Klamminger G, Rawitzer J, Sichward L, Hadaschik B, et al.
J Pathol Clin Res
. 2025 Jan;
11(1):e70017.
PMID: 39817402
Distinct molecular subtypes of muscle-invasive bladder cancer (MIBC) may show different platinum sensitivities. Currently available data were mostly generated at transcriptome level and have limited comparability to each other. We...
2.
Olah C, Sichward L, Hadaschik B, Darr C, Grunwald V, Krafft U, et al.
BJU Int
. 2025 Jan;
PMID: 39801278
Objective: To investigate the expression patterns of Nectin-4, the target molecule of the antibody-drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC)....
3.
Olah C, Mairinger F, Wessolly M, Joniau S, Spahn M, Kruithof-de Julio M, et al.
Prostate Cancer Prostatic Dis
. 2024 Nov;
PMID: 39543244
Background: Localized prostate cancer (PCa) is a largely heterogeneous disease regarding its clinical behavior. Current risk stratification relies on clinicopathological parameters and distinguishing between indolent and aggressive cases remains challenging....
4.
Olah C, Kubik A, Matrai P, Engh M, Barna V, Hegyi P, et al.
Urol Oncol
. 2024 Apr;
42(7):221.e1-221.e7.
PMID: 38627107
Background: Urachal cancer (UrC) is a rare disease with limited availability of representative incidence and clinical data. Although, the prevalence is accounting for less than 1% of bladder tumors, the...
5.
Fritz P, Fritz R, Boday P, Boday A, Bato E, Kesseru P, et al.
J Int Soc Sports Nutr
. 2023 Dec;
21(1):2297992.
PMID: 38151716
Background: Sufficient protein intake is essential for adequate physical condition and athletic performance. However, numerous factors can influence the absorption of consumed protein, including timing, type of protein intake, and...
6.
Varadi M, Horvath O, Modos O, Fazekas T, Grunewald C, Niegisch G, et al.
Sci Rep
. 2023 Oct;
13(1):17378.
PMID: 37833455
Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus...
7.
Olah C, Szarvas T
Methods Mol Biol
. 2023 Jul;
2684:27-43.
PMID: 37410226
Transcriptome-based molecular subtype classification of muscle-invasive urothelial bladder cancer was shown to have prognostic and therapy-predictive relevance and thus may help to inform therapeutic decision-making. However, current classification systems rely...
8.
Koll F, Doring C, Olah C, Szarvas T, Kollermann J, Hoeh B, et al.
BMC Cancer
. 2023 Jun;
23(1):504.
PMID: 37270477
Background: Molecular subtypes predict prognosis in muscle-invasive bladder cancer (MIBC) and are explored as predictive markers. To provide a common base for molecular subtyping and facilitate clinical applications, a consensus...
9.
Varadi M, Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O, et al.
Cancer Med
. 2023 Jan;
12(7):9041-9054.
PMID: 36670542
Objective: Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma (PBAC); however, the selection of appropriate drugs remains difficult. Here, we aimed...
10.
Szeles A, Kovacs P, Csizmarik A, Varadi M, Riesz P, Fazekas T, et al.
Biomedicines
. 2022 Oct;
10(10).
PMID: 36289821
Programmed death ligand-1 (PD-L1) is an immune checkpoint molecule and a widely used therapeutic target in urothelial cancer. Its circulating, soluble levels (sPD-L1) were recently suggested to be associated with...